Research library

Tesamorelin Research Overview: GHRH Receptor Pharmacology, Randomised Trial Evidence and Interpretation Limits

Compiled by:: Peptide Pilots Scientific Content Team
Reviewed by:: Peptide Pilots Quality & Compliance review
Last revised:: 3 September 2026

What is the strongest published evidence for tesamorelin, and which endpoints does it actually cover?

Tesamorelin is a stabilised analogue of human growth hormone-releasing hormone (1-44) amide bearing an N-terminal trans-3-hexenoyl group. It is the growth hormone secretagogue class member with the most substantial randomised human evidence: two phase 3 trials in HIV-associated abdominal lipodystrophy reported reductions in visceral adipose tissue measured by CT, and later randomised studies reported reductions in liver fat measured by MRS in people with HIV and hepatic steatosis. The evidence base is specific to those populations and endpoints, and IGF-1 elevation and glucose-tolerance changes are recurring interpretive caveats.

This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.

What is Tesamorelin?

Tesamorelin is a 44-amino-acid peptide corresponding to human GHRH(1-44) amide with a hexenoyl modification at the N-terminus that reduces DPP-4 cleavage and extends exposure relative to native GHRH.

In laboratory work it is used as a GHRH receptor (GHRHR) reference agonist in pituitary cell assays and animal models of the GH/IGF-1 axis, and in adipose-tissue metabolism research.

Tesamorelin names and identifiers

Also referred to as: TH9507; trans-3-hexenoyl-GHRH(1-44) amide; GHRH analogue; Egrifta (approved product name)

Molecular formula	C221H366N72O67S
Average molecular weight	≈5135.9 g/mol
CAS number	218949-48-5
Development code	TH9507
Molecular target	Growth hormone-releasing hormone receptor (GHRHR, UniProt Q02643)
Database records	DrugBank DB08869; approved in the United States for HIV-associated lipodystrophy
Registry records	ClinicalTrials.gov NCT00123253 and NCT00435136 (phase 3 programme)

Tesamorelin research background

GHRH was isolated in 1982 from pancreatic tumours causing acromegaly, and the 1-29 fragment was shown to retain full biological activity, which enabled the development of shorter analogues such as sermorelin.

Native GHRH has a very short half-life because of DPP-4 cleavage at the position 2 alanine. Tesamorelin's hexenoyl modification was designed to resist that cleavage while retaining receptor activity.

Development targeted HIV-associated lipodystrophy, a condition with reduced endogenous GH secretion and excess visceral adipose tissue, which provided a defined population and a quantifiable imaging endpoint. Later research questions concerned hepatic steatosis and cognitive endpoints in ageing populations.

Proposed Tesamorelin mechanisms and pathways

Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.

Tesamorelin in-vitro and cell-based evidence

Binds GHRHR, a class B GPCR expressed on pituitary somatotrophs, activating Gs, adenylate cyclase and cAMP-dependent GH gene transcription and secretion.
Because it acts upstream of the pituitary, secretion retains pulsatility and negative feedback from IGF-1 and somatostatin, unlike exogenous growth hormone administration.

Tesamorelin animal-model evidence

Animal pharmacology confirmed increased GH pulse amplitude and downstream hepatic IGF-1 production with preserved feedback regulation.
Adipose-tissue studies attribute visceral fat reduction to GH-mediated lipolysis, with visceral depots reported as more GH-responsive than subcutaneous depots.

Published Tesamorelin human-study evidence

Two 26-week randomised phase 3 trials in HIV-associated abdominal fat accumulation reported mean visceral adipose tissue reductions of roughly 15-18% versus placebo, with partial regression after withdrawal in extension phases.
A randomised trial in people with HIV and hepatic steatosis reported reduced hepatic fat fraction by MRS and less fibrosis progression on biopsy over 12 months.
Studies in older adults reported IGF-1 increases with modest cognitive-measure differences; these are small studies and are not confirmatory.

Published Tesamorelin studies

Selected published studies involving Tesamorelin
Study	Model / type	Research question	Main observation	Citation
Falutz et al., phase 3 lipodystrophy trial	Human, 412 participants with HIV-associated abdominal fat accumulation, 26 weeks	Does GHRH-analogue therapy reduce visceral adipose tissue?	Mean visceral adipose tissue reduction of about 15% versus placebo, measured by CT.	New England Journal of Medicine, 2007
Falutz et al., confirmatory trial and extension	Human, second phase 3 trial with 26-week extension	Are the effects reproducible and durable after withdrawal?	Findings reproduced; visceral fat regressed toward baseline after discontinuation.	Journal of Clinical Endocrinology & Metabolism, 2010
Stanley et al., hepatic fat trial	Human, randomised placebo-controlled, 12 months, HIV with steatosis	Does tesamorelin reduce liver fat and fibrosis progression?	Reduced hepatic fat fraction by MRS and less fibrosis progression on paired biopsy.	The Lancet HIV, 2019
Baker et al., cognition study	Human, older adults with and without mild cognitive impairment, 20 weeks	Does GHRH administration affect cognitive measures?	Favourable differences on executive-function measures in a small study; not independently confirmed.	Archives of Neurology, 2012

Limitations of the Tesamorelin evidence

The pivotal evidence is confined to HIV-associated lipodystrophy; extrapolation to general visceral adiposity is not supported by equivalent randomised data.
Effects regress after discontinuation, so the studied outcomes are exposure-dependent rather than durable modifications.
IGF-1 rises during exposure, and trials excluded participants with active malignancy; long-term oncological safety data at the population level are limited.
Glucose tolerance can worsen with GH-axis stimulation; trials reported changes in glycaemic measures that require consideration when interpreting metabolic benefits.
Cognition and hepatic findings come from single-centre or modest-sized studies and await independent replication.
Trials were sponsor-supported, and imaging endpoints, while objective, are surrogate measures rather than clinical outcomes.

Tesamorelin laboratory characteristics

Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.

Appearance	White to off-white lyophilised powder
Solubility	Soluble in sterile water and aqueous buffers; large peptides of this class are sensitive to vigorous agitation
Lyophilised storage	Commonly stored at −20 °C, desiccated and light-protected
Reconstituted handling	Kept cold, protected from light, and not refrozen after reconstitution
Analytical testing	RP-HPLC purity, MS identity, and peptide-content determination; 44-residue peptides commonly report related-substance profiles
Stability considerations	Methionine oxidation, asparagine deamidation and aggregation are the routes generally monitored

Frequently asked Tesamorelin research questions

How does tesamorelin differ from growth hormone itself?

It stimulates the pituitary to release endogenous growth hormone through the GHRH receptor, so secretion remains pulsatile and subject to somatostatin and IGF-1 feedback, unlike exogenous GH administration.

How does it differ from sermorelin?

Sermorelin is the GHRH(1-29) fragment with a very short half-life. Tesamorelin is the full 1-44 sequence with an N-terminal hexenoyl group that resists DPP-4 cleavage and extends exposure.

What endpoints do the phase 3 trials actually cover?

CT-measured visceral adipose tissue in adults with HIV-associated abdominal fat accumulation over 26 weeks, plus lipid and IGF-1 measures. They do not cover general weight management.

Why is IGF-1 monitored in this research?

Because GHRH-receptor agonism raises hepatic IGF-1 production, IGF-1 is used both as a pharmacodynamic marker of target engagement and as a safety parameter in published trials.

Tesamorelin primary references

Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa072375
Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin on visceral fat and metabolic parameters: pooled phase 3 analysis. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0697
Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, placebo-controlled trial. The Lancet HIV. https://doi.org/10.1016/S2352-3018(19)30338-8
Baker LD, Barsness SM, Borson S, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. https://doi.org/10.1001/archneurol.2012.1970

Authorship and revision

Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published 14 August 2026; last revised 3 September 2026. Pages are revised when the cited literature changes materially.

Catalogue reference

Peptide Pilots supplies Tesamorelin as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.

View Tesamorelin catalogue entry